Edwards lifesciences reports fourth quarter results

Irvine, calif.--(business wire)--edwards lifesciences (nyse: ew) today reported financial results for the quarter and full-year ended dec. 31, 2024. highlights and outlook q4 sales grew 9% to $1.39 billion1, better than expected, with strength across all product groups q4 tavr sales grew 6%; constant currency2 sales grew 5% q4 tmtt sales grew 88% to $105 million with increasing contribution to edwards' growth q4 eps of $0.581; adjusted2 eps of $0.59, driven by strong top-line performance presen.
EW Ratings Summary
EW Quant Ranking